Literature DB >> 30082413

Maelstrom Directs Myeloid-Derived Suppressor Cells to Promote Esophageal Squamous Cell Carcinoma Progression via Activation of the Akt1/RelA/IL8 Signaling Pathway.

Pupu Li1,2, Xinfeng Chen1,2, Guohui Qin1,2, Dongli Yue2, Zhen Zhang1, Yu Ping1, Dan Wang1,2, Xuan Zhao1, Mengjia Song1,2, Qitai Zhao1,2, Jieyao Li2, Shasha Liu1, Dong Wang1,2, Chaoqi Zhang1,2, Jingyao Lian1, Ling Cao1,2, Feng Li1, Lan Huang1, Liping Wang2, Li Yang1, Jianmin Huang1, Hong Li1, Bin Zhang1,3, Yi Zhang4,2,5,6.   

Abstract

Maelstrom (MAEL) is a novel cancer/testis-associated gene, which is not only expressed in the male testicular germ cells among human normal tissues, but is also aberrantly expressed in various cancer tissues. In our study, MAEL was characterized as a tumor-promoting gene and was significantly associated with esophageal squamous cell carcinoma (ESCC) recurrence and unfavorable prognosis. Kaplan-Meier analysis showed that patients with high MAEL expression had a shorter survival time. Functional experiments showed that MAEL promoted tumor cell growth and inhibited cell apoptosis. These results prompted us to investigate the factors affecting the tumorigenicity of MAEL Further experimentation demonstrated that MAEL enhanced the expression of phosphorylated Akt1, with subsequent phosphorylation of nuclear factor kappa B (NF-κB) subunit RelA in tumor cells, and chemoattracted myeloid-derived suppressor cells (MDSCs) by upregulating interleukin-8 (IL8) to accelerate tumor progression in the tumor microenvironment. We also found that TGFβ secreted by MDSCs could upregulate MAEL by inducing Smad2/Smad3 phosphorylation. In summary, this study revealed a mechanism by which MAEL could upregulate IL8 through Akt1/RelA to direct MDSCs homing into the tumor, suggesting that MAEL could be an attractive therapeutic target and a prognostic marker against ESCC. Cancer Immunol Res; 6(10); 1246-59. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30082413     DOI: 10.1158/2326-6066.CIR-17-0415

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  15 in total

1.  MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis.

Authors:  Chaoran Shi; Dora Lai-Wan Kwong; Xue Li; Xia Wang; Xiaona Fang; Liangzhan Sun; Ying Tang; Xin-Yuan Guan; Shan-Shan Li
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

2.  L1CAM overexpression promotes tumor progression through recruitment of regulatory T cells in esophageal carcinoma.

Authors:  Xuan Zhao; Shasha Liu; Xinfeng Chen; Jianyi Zhao; Feng Li; Qitai Zhao; Tan Xie; Lan Huang; Zhen Zhang; Yu Qi; Yang Yang; Song Zhao; Yi Zhang
Journal:  Cancer Biol Med       Date:  2021-03-12       Impact factor: 4.248

3.  Maelstrom promotes tumor metastasis through regulation of FGFR4 and epithelial-mesenchymal transition in epithelial ovarian cancer.

Authors:  Wei-Peng He; Gui-Ping Yang; Zun-Xian Yang; Hong-Wei Shen; Ze-Shan You; Guo-Fen Yang
Journal:  J Ovarian Res       Date:  2022-05-06       Impact factor: 4.234

4.  Identification of an individualized RNA binding protein-based prognostic signature for diffuse large B-cell lymphoma.

Authors:  Yongzhi Xie; Ximei Luo; Haiqing He; Tao Pan; Yizi He
Journal:  Cancer Med       Date:  2021-03-21       Impact factor: 4.452

5.  MAEL as a diagnostic marker for the early detection of esophageal squamous cell carcinoma.

Authors:  Mohammad Reza Abbaszadegan; Negin Taghehchian; Azadeh Aarabi; Faride Akbari; Ehsan Saburi; Meysam Moghbeli
Journal:  Diagn Pathol       Date:  2021-04-26       Impact factor: 2.644

6.  PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF-κB/IL8 pathway.

Authors:  Lingling Fang; Yun Che; Chaoqi Zhang; Jianbing Huang; Yuanyuan Lei; Zhiliang Lu; Nan Sun; Jie He
Journal:  Cell Death Discov       Date:  2021-02-11

7.  NEDD9 promotes cancer stemness by recruiting myeloid-derived suppressor cells via CXCL8 in esophageal squamous cell carcinoma.

Authors:  Dongli Yue; Shasha Liu; Tengfei Zhang; Yong Wang; Guohui Qin; Xinfeng Chen; Huanyu Zhang; Dong Wang; Dong Huang; Feng Wang; Liping Wang; Song Zhao; Yi Zhang
Journal:  Cancer Biol Med       Date:  2021-03-12       Impact factor: 4.248

Review 8.  Role of immune escape in different digestive tumours.

Authors:  Xin-Zhu Du; Bin Wen; Lin Liu; Ying-Ting Wei; Kui Zhao
Journal:  World J Clin Cases       Date:  2021-12-06       Impact factor: 1.337

9.  IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients.

Authors:  Richard P Tobin; Kimberly R Jordan; Puja Kapoor; Eric Spongberg; Dana Davis; Victoria M Vorwald; Kasey L Couts; Dexiang Gao; Derek E Smith; Jessica S W Borgers; Steven Robinson; Carol Amato; Rene Gonzalez; Karl D Lewis; William A Robinson; Virginia F Borges; Martin D McCarter
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

10.  LAMC1 upregulation via TGFβ induces inflammatory cancer-associated fibroblasts in esophageal squamous cell carcinoma via NF-κB-CXCL1-STAT3.

Authors:  Lingling Fang; Yun Che; Chaoqi Zhang; Jianbing Huang; Yuanyuan Lei; Zhiliang Lu; Nan Sun; Jie He
Journal:  Mol Oncol       Date:  2021-07-22       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.